Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

J&J Growth Plans Heavy On Line Extensions, Sticking With Immunology And Oncology

Executive Summary

Recent launches Tremfya and Erleada are viewed as catalysts for continuing growth, along with ambitious plans to add indications for Imbruvica, Darzalex and Stelara.

Advertisement

Related Content

Keeping Track: An Approval For Ajovy, A CRL For Ruconest, And Some Submissions from J&J
At J&J, Oncology Closes In On Immunology As The Leading Pharma Franchise
How The Prostate Cancer Market Will Look Over Next Decade
J&J's First-In-Class Tremfya Poised To Join A Crowded Psoriasis Market
J&J Plots Five-Year Pharma Growth Plan Around Mega-Brands And Launches
New Crohn’s Indication Puts Janssen’s Stelara On Equal Ground With Anti-TNFs
Janssen Oncology Strategy: Take A Holistic Approach To R&D

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

SC123843

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel